Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents

ClinicalTrials.gov ID: NCT03813238

Public ClinicalTrials.gov record NCT03813238. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 2:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents

Study identification

NCT ID
NCT03813238
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Enrollment
63 participants

Conditions and interventions

Interventions

  • TEV-50717 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
6 Years to 18 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 5, 2019
Primary completion
Jul 4, 2022
Completion
Jul 20, 2022
Last update posted
Sep 7, 2023

2019 – 2022

United States locations

U.S. sites
23
U.S. states
17
U.S. cities
22
Facility City State ZIP Site status
Teva Investigational Site 14137 Birmingham Alabama 35233
Teva Investigational Site 14224 Phoenix Arizona 85016
Teva Investigational Site 14227 Loma Linda California 92354
Teva Investigational Site 14295 San Diego California 92123
Teva Investigational Site 14293 Washington D.C. District of Columbia 20010
Teva Investigational Site 14127 Miami Florida 33155
Teva Investigational Site 14125 Tampa Florida 33609
Teva Investigational Site 14136 Atlanta Georgia 30318
Teva Investigational Site 14291 Atlanta Georgia 30328
Teva Investigational Site 14130 Savannah Georgia 31406
Teva Investigational Site 14290 New Orleans Louisiana 70118-5720
Teva Investigational Site 14226 Saint Paul Minnesota 55101
Teva Investigational Site 14134 Lincoln Nebraska 68526
Teva Investigational Site 14122 Gibbsboro New Jersey 08026
Teva Investigational Site 14297 New Brunswick New Jersey 08901
Teva Investigational Site 14225 New York New York 10032
Teva Investigational Site 14123 Rochester New York 14642
Teva Investigational Site 14348 Portland Oregon 97239
Teva Investigational Site 14299 Charleston South Carolina 29414
Teva Investigational Site 14129 Nashville Tennessee 37232
Teva Investigational Site 14228 Houston Texas 77030
Teva Investigational Site 14223 Richmond Virginia 23298
Teva Investigational Site 14135 Everett Washington 98201

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 47 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03813238, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 7, 2023 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03813238 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →